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ABSTRACT 
Objective: The objective of using natural polymer was to modify the 
release rate of Diclofenac sodium from matrix tablet. The matrix forming 
agent like Tamarind seed Polysaccharide show sustained release property 
in tablet which is obtained naturally from fruit of Tamarindus indica L. 
belonging to Family Leguminosae. 
Methods: The sustained release matrix tablet of Diclofenac sodium were 
prepared by wet granulation technique using varying concentration of 
hydrophilic polymer i.e. TSP. 
Results: OF1 and OF2 both are optimized batch. The in vitro dissolution 
study was carried out for optimized as well as marketed formulation 
(Voveran- SR). Both the optimized batchesat 10 h were found to be 
90.27% and 90.18%, respectively. 
Conclusions: Tamarind seed polysaccharide can be employed in dosage 
form to sustain the drug release. Tablet formulated with various 
concentrations of Tamarind seed polysaccharide (TSP) gives release up to 
10 h and more. OF1 and OF2 both formulations give comparable release 
with marketed formulation. From the present work it can be conclude that, 
the objectives which were set at the beginning of the study got fulfilled. 
Keywords: Diclofenac sodium, Tamarid seed polysaccharide, Matrix forming 
agent 
 
Introduction 
Tamarind is amongst most common and 
commercially important large evergreen tree that 
is grown abundantly in the dry tracks of Central 
and South Indian states, and also in other South 
East Asian countries. Following parts of fruit 
of Tamarindus indica L. belonging to the family 
Leguminosae are commercially very important: 
Pulpy portion of the fruit mainly used as 
acidulate in Indian recipes. Tamarind gum is 
obtained from the kernel of the seeds powder. 
Tamarind products are widely used in Asia and 
also used in some part of Africa. In Asian 
countries, especially India, tamarind is mainly 
cultivated and used as a gelling, and acidifying 
agent.  Tamarind gum along with xanthan gum, 
hydroxypropyl cellulose is used for nasal 
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mucoadhesion studies in powder 
formulation.  Tamarind gum is also used for as a 
bioadhesive tablet.1,16,20,23,24,27 
Matrix tablets composed of drug and polymer as 
release retarding material offer the simplest 
approach in development a sustained release 
system. For sustained release systems, the oral 
route of drug administration has received the 
most interest as it is natural, uncomplicated, 
convenient and safer route. Matrix tablets were 
prepared by direct compression method. 
Mucilages are composed of heterogenous 
polysaccharide complexes formed fromthe 
sugars, arabinose, galactose, glucose, mannose, 
xylose and uronic acid units. Mucilages possess 
a variety of pharmaceutical properties, which 
make them useful as additives in pharmaceutical 
preparations and in present investigations, 
mucilages plays important role in design of 
formulations.2-7,14,21,23 
Materials and Methods 
Materials 
Diclofenac Sodium, Tamarind Seed 
Polysaccharide 
Method of extraction of tamarind gum 
Method 1 
200 g of tamarind seeds was soaked in double 
distilled water and boiled for 5 hr to remove the 
outer dark layer. Often the outer dark layer is 
removed, to the inner white portion sufficient 
amount of double distilled water was added and 
boiled with constant stirring to prepare the 
slurry. Now cool the resultant solution in 
refrigerator so that most of the undisclosed 
portion settles down. The supernatant liquid can 
be separated out by simple decantation or best 
by centrifugation at 500 rpm for 20 min. After 
this, the solution is concentrated on a water bath 
at 60°C to reduce the volume to one-third of the 
initial volume. Now cool the solution and pour 
into 3 volumes of acetone by continuous stirring. 
Precipitates obtained were washed with acetone 
and drying in vacuum at 50-60°C.1,8,9,11-13,15 
 
Method 2 
Tamarind seeds were collected and dried in 
sunlight. The kernels are than crushed to fine 
powder. 20 g of fine kernel powder was added to 
200 ml of cold distilled water to prepare slurry. 
The slurry obtained is than poured into 800 ml 
of boiling distilled water and are boiled for 20 
min on a water bath; a clear solution was 
obtained which was kept overnight. The thin 
clear solution was than centrifuged at 5000 rpm 
for 20 min to separate all the foreign matter. 
Supernatant liquid was separated and poured 
into excess of absolute alcohol with continuous 
stirring. Precipitates were obtained which were 
collected by a suitable method and washed with 
200 ml of absolute ethanol and dried at 50°C for 
10 hr. Store the polymer obtained in 
desiccators.17-19, 24-26 
Method 3 
This method is patented in United States by 
Jones et al. It involves the separation of tamarind 
kernel powder on the basis of their size 
distribution. Tamarind kernel powder was 
defatted by using C-6 or C-8 aromatic 
hydrocarbons or C-1 or C-2 or above 
halogenated lower hydrocarbons or C-1 or C-5 
mono or dihydroxy alcohols, e.g. ethylene 
dichloride, heptanes, or toluene. (For defatting 
Crude TKSP is suspended in suitable solvent to 
extract fat that is mechanically recovered by 
filtration or centrifugation and dried.) After 
drying, HiSil or other silicaceous materials like 
CabOSil improve the flow properties of powder. 
The powder is further grounded by using 
Hammer mill or Pin mill that will reduce the size 
of the powder below 100 mm. The powder is 
further air classified by using suitable air 
classifier. Three fractions of the powder were 
obtained after air classifications: 10-20% of fine 
fraction rich in protein.60-80% of moderately 
fine fraction rich in polysaccharides.10-20% of 
the coarser fraction rich in mechanical 
properties. TSP can be isolated from the 
moderately fine powder fraction of the powder 
obtained after air classification.[10,22,28,29,30] 
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Results and Discussion 
1)   Characterization of Diclofenac sodium 
a) Melting point of Diclofenac sodium: The 
melting point was found to be in the range of 
280 to 2820c. 
b) Spectroscopic studies 
UV spectroscopy: (Determination of λ max.) 
The UV spectrum obtained is shown in Figure 1. 
The wavelength of maximum absorbance (λ 
max) was found to be 276 nm in Methanol (A.R. 
grade) and Phosphate buffer pH 6.8. 
 
Figure 1: UV spectra of Diclofenac sodium. 
Preparation of standard curve (calibration 
curve) of Diclofenac Na in Phosphate Buffer 
(pH 6.8) 
Table 1: Data of concentration and 
absorbance. 
Sr. No. Concentration 
(μg/ml) 
Absorbance 
at 276 nm 
1 2 0.1012 
2 4 0.1891 
3 6 0.2492 
4 8 0.3219 
5 10 0.3991 
6 12 0.4849 
7 14 0.5972 
The graph of absorbance versus concentration 
for pure Diclofenac sodium is shown in Figure 
2. It was found to be linear in the concentration 
range of 2-14 µg/ml at 276 nm. Hence the drug 
obeys the Beer’s- Lambert law in this range. 
Table 2: Data for standard curve parameters. 
Sr. No. Parameters Values 
1 Correlation coefficient 
(R) 
0. 922 
2 Slope 0.039 
3 Intercept 0.016 
 
Figure 2: Calibration curve of Diclofenac 
sodium in phosphate buffer (pH 6.8). 
Preparation of standard curve (calibration 
curve) of Diclofenac Na In 0.1 N HCl. 
Table 3: Data of concentration and 
absorbance. 
Sr. No. Concentration 
(μg/ml) 
Absorbance 
at 276 nm 
1 2 0.0993 
2 4 0.1338 
3 6 0.1721 
4 8 0.1935 
5 10 0.229 
 
Figure 3: Calibration curve of Diclofenac Na 
in 0.1 N. HCl (absorbance vs concentration). 
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IR spectrum interpretation 
Infrared spectrum of Diclofenac sodium was 
recorded. The observed peaks are match with the 
peaks given in pharmacopoeia which confirms 
that the supplied samples was of Diclofenac 
sodium. 
Table 4: Data for standard curve parameters. 
Sr. No. Parameters Values 
1 Correlation 
coefficient (R) 
0. 992 
2 Slope 0.016 
3 Intercept 0.069 
 
Figure 4: FTIR spectrum of Diclofenac 
sodium. 
Table 5: IR spectrum interpretation of 
Diclofenac sodium. 
Sr. No. Frequency (cm-
1) 
Assignment 
1 3454.54 cm-1 N-H stretching 
2 1591cm-1 N-H bending 
3 748.38cm-1 C-Cl Stretching 
4 1153.57cm-1 Ar-H Bending 
5 778.9,715.59,66
7.37cm-1 
Disubstituted chlorine 
6 1539.20cm-1 CH2 Deformation 
7 1712.79,1759.08
cm-1 
C=O Stretching 
 
2) Tests for Tamarind seed polysaccharide 
a) Preliminary test for Tamarind seed 
polysaccharide 
Table 6: Identification test for TSP. 
Sr. No. Test Result 
1 Swelling by 
ethanol solution 
Negative 
2 Colour reaction 
with conc HCl 
Yellow 
3 Colour reaction 
with 5N  NaOH 
Yellow 
Identification test for tamarind seed 
polysaccharide was performed as per article as 
all result found to be positive from above  result 
it confirmed that powder  obtained  shows gum 
property . 
 b)   Determination of purity of polysaccharide 
(+ Present; - Absent) 
Table shows determination of purity of polysa 
ccharide by using various tests. Result obtained 
shows that polysaccharide which was extracted 
is pure as result obtained are negative only 
carbohydrates test are positive. 
Table 7: Test for purity of gum. 
Sr. 
No. 
Tests T.  indica 
1. Tests for steroids: Salkowski 
test, Liebermann- burchard test 
-ve 
2. Tests for triterpenoids: 
Salkowski test, Libermann-
Burchard test 
-ve 
3. Tests for saponins: Foam test, 
Haemolysis test 
-ve 
4. Tests for carbohydrates: 
Molisch test, Barfoed’s test 
Benedicts test 
+ve 
5. Tests for alkaloids: Mayer’s 
test, Hager’s test, 
Dragendorff’s test 
-ve 
6. Tests for flavonoids(after 
hydrolysis) Shinoda test, 
Zinc/HCL reduction test 
-ve 
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c) Confirmatory tests for extracted 
polysaccharide 
Table 8: Confirmatory tests for extracted 
polysaccharide. 
Sr. 
No. 
Test Observation Inference 
1. Molisch Test: 
2ml of sample 
solution (1%w/v) 
with 5 drops of 
Molisch’s reagent 
in a test tube. Add 
gently through the 
side of test tube, 
about 2 ml of 
Conc. Sulphuric 
acid. 
 
Violet ring 
at the 
junction of 
two liquids 
was seen 
Carbohydrate 
present 
2. Solubility: 
Sample + Water 
Sparingly 
soluble 
Polysaccharide 
Present. 
 
3. C.T. For glucose: 
2 ml of test 
solution+5%NaoH 
Solution 
 
Brown 
precipitate 
was 
observed. 
 
Glucose 
Confirm. 
 
4. Foulger’s Test: 
3 ml of Foulgers's 
reagent+1 ml test 
sol. Boil for 45 
seconds and shake 
well. 
Foulger’s 
Reagent: 40 g of 
urea in 80 ml of 
sulphuric acid 
(40% v/v) then 
add 2 g of 
stannous chloride 
boil until clear 
solution obtain. 
 
Blue green 
color was 
developed 
 
Galactose and 
xylose confirm 
 
3) Physiochemical characterization of TSP 
a) Physical Parameters 
i) Organoleptic properties: 
Yellowish cream colour of the polymer was 
observed. 
 
b) Solubility: 
Table 9: Solubility of TSP. 
Sr. No. Solvent Solubility 
1. Water Sparingly soluble 
2. Warm water viscous colloidal 
solution 
3. Chloroform Insoluble 
4. Ethanol (95%) Insoluble 
5. Isopropyl alcohol Insoluble 
6. Dichloromethane Insoluble 
c) Loss on Drying: 
The loss on drying of TSP was found to be 6.78 
%. 
d) Angle of Repose: 
The angle of repose of polymer was found to be 
26.10 ± 0.13 which means powder has good 
flow property. 
e) Density: 
i) Bulk Density: Bulk density of powder was 
found to be 0.6410 ± 0.0069 g/ml 
ii) Tapped Density: Tapped density of powder 
was found to be 0.7462 ± 0.0091 g/ml 
f) Compressibility index: 
Compressibility index of powder was found to 
be 14.07 ± 1.696 % which shows that powder 
has good flow property. 
g) Hausner’s ratio: 
Hausner’s ratio of powder was found to be 1.45 
± 0.058 which indicate that powder has good 
flow property. 
h) Viscosity measurement: 
The viscosity of 1 % (w/v) TSP solution was 
found to be 257.4 ± 0.01 cps. 
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i) Melting point determination 
Melting point of TSP was measured and it was 
found that the material showed charring instead 
of melting in the range of 250 ºC - 260 ºC. 
j) Infrared spectroscopy 
Fourier transform infrared (FTIR) spectra of the 
samples were obtained in the range of 400 to 
4000 cm-1 using a FTIR Spectrophotometer by 
the KBr disc method. The FTIR spectrum of 
TSP is shown in Figure 5. 
 
Figure 5: FTIR spectrum of TSP. 
Interpretation 
Table gives the interpretation of the peaks 
obtained in the IR spectra along with their 
corresponding functional groups. From the FTIR 
spectra it is observed that, the peaks at 1083.99 
cm-1 indicates presence of C-O  stretch, 3388.93 
cm-1  O-H stretching,1083.99 cm-1 C-C 
stretching. 
Table 10: IR spectrum interpretation of TSP. 
Sr. No. Frequency (cm-1) Assignment 
1. 3388.93 cm-1 O-H stretch 
2. 2929.87 C-H Stretch 
3. 1649.14,1462.04 CH2-Stretch 
4. 1367.53,1242.16 OH-Plane bend 
5. 1157.29 Glycosidic linkage 
6. 1083.99 Coupled CO Stretch 
7. 927.76 Ring Vibration 
Drug - polymer compatibility study 
The IR spectrum did not show presence of any 
additional peaks for new functional groups 
indicating no chemical interaction between 
diclofenac sodium and Tamarind seed 
polysaccharide. 
FTIR spectrum of Diclofenac sodium and TSP 
 
Figure 6: FTIR spectrum of Diclofenac 
sodium and TSP. 
Evaluation of granules 
Loose bulk density (LBD) and Tapped bulk 
density (TBD) 
Bulk density depends upon particle size, shape, 
and tendency of particles to adhere together. The 
value for LBD and TBD has been shown in 
Table 11.  These were found in the range of 
0.516 0.007 g/ml to 0.58830.01 g/ml and 
0.56050.005 g/ml to 0.65790.007 g/ml for 
granules respectively. Bulk densities of blends 
were found to be quite high which indicates that 
there is no excessive air voids and hence the 
granule mass do not pose any problem during 
compression. i.e. These values may further be 
correlate with compressibility index and tablet 
dissolution. 
Angle of repose and compressibility index 
The values of angle of repose have been shown 
in Table 11. The angle of repose and 
Compressibility Index of granules were found in 
the range of 25.980.3 to 28.26 1.86 and 
7.112.99 % to 12.66 1.245 % respectively. 
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Lubrication with magnesium stearate and talc 
improved the flow property. 
6. Evaluation of tablets 
The results are shown in Table 12. 
7. Physical parameters 
Thickness 
Tablets has shown thickness values in the range 
of 3.14  0.03 mm to 3.67  0.02 mm. 
Weight variation test 
The pharmacopoeial limits for deviation for 
tablets of more than 250 mg are ± 5%. The 
average percentage deviation for all tablet 
formulations was found to be within the 
specified limits and hence all formulations 
complied with the test for weight variation. 
Hardness and friability 
The tablets showed hardness values ranging 
from 4.93  0.09 to 5.93  0.09 kg/cm2,  
However these values alone cannot be 
considered as absolute indicator of their 
strength. Another measure of a tablet’s strength 
is friability. Conventional compressed tablets 
that lose less than 1% of their weight are 
generally considered acceptable. In present 
study, the friability values for all the tablet 
Table 11: Data for evaluation of granules. 
Sr.No. Formulations Loose Bulk 
Density (LBD) 
(g/ml) 
Tapped Bulk 
Density (TBD) 
(g/ml) 
Compressibility 
Index 
(%) 
Angle of 
Repose 
(θ) 
1. F1 0.5883 0.01 0.6270.003 9.4471.77 27.960.06 
2. F2 0.52530.004 0.5850.008 10.280.645 26.630.27 
3. F3 0.5160.007 0.57330.005 10.0030.386 26.490.63 
4. F4 0.5330.007 0.5930.006 10.160.302 28.261.86 
5. F5 0.5200.018 0.56050.005 7.112.99 27.300.40 
6. F6 0.53740.009 0.59770.0089 10.061.72 27.340.45 
7. F7 0.52170.011 0.5970.0087 12.661.245 27.050.40 
8. F8 0.55340.003 0.61960.003 10.670.899 25.980.3 
9. F9 0.58440.004 0.65790.007 11.150.471 26.490.4 
All Values are expressed as mean ± SD, n=3. 
Table 12: Physical evaluation data for the compressed tablets containing various concentrations of 
polymer. 
Sr.No. Form
ulati
ons 
Thickness 
(mm) 
Weight 
Variation 
Hardness 
(Kg/cm2 ) 
Friability 
(%) 
Uniformity of 
Drug Content 
(%) 
1. F1 3.14  0.03 348.86  0.440 5.73  0.249 0.260  0.047 99.8  0.60 
2. F2 3.35  0.02 348.88  0.510 5.53  0.52 0.226 ± 0.055 99.3  0.57 
3. F3 3.52  0.01 348.43  0.88 5.73  0.24 0.22  0.0326 98.7  0.98 
4. F4 3.36  0.04 348.45  1.30 5.46  0.24 0.37  0.074 99.9  0.65 
5. F5 3.65  0.02 348.14  0.855 5.46  0.09 0.323  0.032 99.1  0.57 
6. F6 3.26  0.08 348.56  0.530 5.26  0.09 0.43  0.0801 99.1  0.65 
7. F7 3.45  0.05 346.91  0.668 5.33  0.09 0.29  0.014 98.0  0.98 
8. F8 3.67  0.02 348.26  0.736 4.93  0.09 0.543  0.112 98.2  0.95 
9. F9 3.65  0.06 348.43  0.922 5.93  0.09 0.363  0.110 98.0  0.98 
All Values are expressed as mean ± SD, n=3. 
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formulations were found to be <1%, indicating 
that the friability is within the prescribed limits. 
Swelling index 
From the above Table 13 and Figure 7 we 
conclude that the process of the drug release 
from tamarind seed polymer involves water 
penetration in to the matrix by hydration and 
swelling of the polymer. As the polymer 
concentration increases, swelling index was 
found to increases up to some duration of time 
and after that limit tablets exhibits its erosion 
and hence swelling index get decreased. The 
swelling behavior indicated the rate at which this 
formulation absorbed water from dissolution 
Table 13: Swelling Index of the tablet batches (F1-F9). 
Sr. 
No 
Swelling index (%) 
 Time 
(Hrs) 
F1 F2 F3 F4 F5 F6 F7 F8 F9 
1 1 29.76 29.45 30.67 29.35 30.35 31.60 33.15 31.27 31.72 
2 2 34.95 35.22 35.89 36.54 36.74 37.79 39.5 37.70 37.80 
3 3 40.85 41.76 41.75 43.77 42.4 43.98 44.35 44.64 44.42 
4 4 44.29 45.03 44.57 46.29 48.89 50.76 52.15 53.29 52.85 
5 5 53.18 54.17 51.41 55.65 57.9 56.17 58.71 57.21 58.28 
6 6 46.47 47.59 48.57 48.85 48.57 51.98 52.0 51.29 51.42 
7 7 42.32 43.55 42.55 43.72 41.44 45.13 43.17 44.11 45.32 
8 8 35.52 36.12 35.43 31.26 34.49 35.96 36.14 37.51 37.71 
9 9 30.11 39.15 28.56 29.85 31.98 31.51 29.14 30.83 29.28 
10 10 26.35 26.11 25.11 25.45 24.29 25.42 25.12 25.75 24.25 
Table 14: The in vitro dissolution profile of diclofenac sodium containing tamarind seed 
polysaccharide matrix tablets (formulations F1 to F4) and marketed tablet. 
Sr. No. Cumulative Percent Drug Release (%) 
 Time 
(Hrs) 
Marketed F1 F2 F3 F4 
1 1 03400.19 12.280.28 8.272.00 5.950.20 5.351.50 
2 2 1.740.29 12.780.21 8.981.84 7.870.70 7.250.97 
3 3 19.452.42 25.5110.2 25.531.28 19.871.08 18.890.24 
4 4 42.60.22 46.341.19 34.252.03 29.230.94 44.651.17 
5 5 47.710.27 52.490.80 47.671.08 36.691.02 53.421.89 
6 6 57.522.21 62.181.07 60.271.00 52.081.22 59.601.22 
7 7 70.671.30 69.080.83 70.501.36 60.840.76 70.820.95 
8 8 75.310.71 77.661.81 79.411.28 73.984.77 77.551.33 
9 9 82.581.27 88.180.20 89.41±1.12 91.750.68 86.391.13 
10 10 90.680.54 96.091.02 95.05±0.75 94.15±1.70 92.520.97 
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media and swelled. It has been observed that the 
cumulative present drug release decreases with 
increasing concentration of the polymer. 
 
Figure 7: Swelling index of the tablet. 
Chemical parameters 
Uniformity of drug content 
Uniformity in drug content was found within 
and among the different types of tablet 
formulations. The values ranged from 98.00.98 
% to 99.90.65 % of labeled amount. Hence the 
tablet prepared passes the pharmacopoeial limit. 
 
Figure 8: Dissolution profile of hydrophilic 
matrix tablets. 
Dissolution test 
The release profiles of Diclofenac sodium from 
the different formulations has been shown in 
Table 14 and Table 15. The data clearly indicate 
the drug release can effectively be sustained by 
varying the concentration of polymer. The batch 
F1, F2, F3….up to F9 showed the drug release 
more than 10 hrs. All the formulations showed 
very low drug release in 0.1 N HCl (pH 1.2). 
This was due to the very low solubility of 
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Table 15: The in vitro dissolution profile of diclofenac sodium containing tamarind seed 
polysaccharide  matrix tablets (formulations F5 to F9). 
Sr. No. Cumulative Percent Drug Release (%) 
Time 
(Hrs) 
F5 F6 F7 F8 F9 
1 1 5.701.34 3.162.94 3.132.67 2.040.86 2.441.04 
2 2 7.740.25 5.920.88 5.452.43 7.420.44 7.170.50 
3 3 18.610.33 17.970.51 16.200.99 15.690.06 15.900.09 
4 4 44.271.76 39.694.47 21.675.07 16.780.70 19.110.13 
5 5 51.671.37 50.052.22 30.141.43 25.920.89 23.850.51 
6 6 59.901.46 57.891.18 46.244.61 30.731.25 33.450.92 
7 7 68.490.86 68.720.53 59.982.37 40.290.93 37.770.82 
8 8 76.681.97 75.862.77 67.371.84 51.131.58 45.581.65 
9 9 83.602.76 80.951.70 70.420.28 60.881.24 65.320.36 
10 10 90.632.21 87.571.88 78.241.47 76.471.15 73.120.99 
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Diclofenac sodium at pH 1.2. Sustained release 
of drug was displayed by all formulations in 
phosphate buffer. The sustained release of drug 
of batch F4, F5, F6 was found to be 92.52±0.973 
%, 90.63±2.2191%, and 87.57±1.8801% 
respectively for a period of 10 hr, where as the 
formulation the sustained release of drug of 
batch F7, F8, F9 not more than 80% within 10hr 
because of comparatively high concentration of 
polymer. 
Table 16 shows application of various kinetic 
models to the dissolution profile. From the data 
it can be conclude that zero order kinetics is best 
fit model for dissolution study. 
Table 17 shows application of various kinetic 
models to the dissolution profile. From the data 
it can be conclude that zero order kinetics is best 
fit model for dissolution study. 
Data treatment for optimization study 
3 D Plot 
The data clearly indicate that the values of drug 
release are strongly dependent on the selected 
Table 16: The dissolution models for matrix tablets (F1-F9) of Diclofenac sodium. 
Sr. No. Formulation code R2 
Zero 
order 
First 
order 
Korsmeyer 
Peppas 
Higuchi Hixson-
Crowell 
model 
1. F1 0.958 0.953 0.893 0.938 0.957 
2. F2 0.985 0.973 0.937 0.953 0.971 
3. F3 0.980 0.971 0.962 0.937 0.945 
4. F4 0.980 0.962 0.957 0.952 0.975 
5. F5 0.976 0.959 0.941 0.952 0.965 
6. F6 0.981 0.967 0.941 0.960 0.973 
7. F7 0.986 0.962 0.950 0.907 0.936 
8. F8 0.981 0.973 0.979 0.929 0.953 
9. F9 0.989 0.951 0.965 0.975 0.981 
Table 17: Table for regression coefficient and best fit kinetic model. 
Sr. No. Batch code Regression coefficient (R) Best fit model 
1. F1 0.958 Zero Order 
2. F2 0.985 Zero Order 
3. F3 0.980 Zero Order 
4. F4 0.980 Zero Order 
5. F5 0.976 Zero Order 
6. F6 0.981 Zero Order 
7. F7 0.986 Zero Order 
8. F8 0.981 Zero Order 
9. F9 0.989 Zero Order 
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independent variables. To demonstrate 
graphically the effect of release modifying 
polymers on the dissolution profile, contour 
plots and 3D graphs were generated. The 3D 
graph as shown in Figure 9. The % drug release 
at 10 hrs is plotted on Y axis where as the 
concentration of independent variable (i.e TSP 
and MCC) were plotted on X and Z axis. As the 
concentration of TSP and MCC increased from 
25 to 75 mg and 70 to140 mg respectively, the 
% drug release decreased signifying that the 
polymers have definite effect on drug release; 
especially along the axis region of TSP the 
effect was greater and prominent. 
 
Figure 9: 3D graph plot showing amount of 
% drug release at tenth hour using different 
combination of TSP and MCC. 
 
Figure 10: Contour plot showing amount of 
drug release at tenth hour (Y1) using 
different combination of X1, X2  The contour 
lines showing percentage of drug release at 
the end of tenth hour. 
The contour plot 
As shown in Figure 10 for % Drug release at 10 
hrs justifies that optimum formulation 
complying with the acceptance criteria can be 
achieved by selecting the formulations near to 
the center of the triangle shaped contour  plot 
which is the diagram obtained from the 
evaluation result of (F1 to F9) formulations. 
Almost similar results were observed with 3D 
graph and contour plot for release at 10hr. Here 
the major effect on the drug release was due to 
TSP. 
Statistical analysis 
Statistical optimization was carried out in design 
expert software (version 8.0.6.1.), which 
suggested that linear model was followed for 
release at 10 hrs with p-value of 0.0005. This 
indicated the model was highly significant. 
Therefore, linear model was selected for percent 
release at ten hours.In order to find out 
contribution of each components and their 
interaction, Analysis of Variance (ANOVA) was 
carried. Table 18 shows the results of the 
analysis of variance (ANOVA), which was used 
to generate mathematical models. The model F-
value (35.59) implied the model was significant. 
Value of probability (p) less than 0.05, indicate 
model terms were significant. In this case, linear 
mixture components, A and B were significant 
model terms (where, A = TSP, B = MCC). The 
equation for percent drug release at the end ten 
hour: 
Y1= +87.09 +8.00* A[1] +3.15* A[2] +1.86* 
B[1] +0.29* B[2] -0.86* A[1]B[1] +0.42  * 
A[2]B[1] -0.34* A[1]B[2] +0.10* A[2]B[2] 
Table 18: ANOVA for selected statistical 
models. 
Sr. No. Response model Release at 10 
hrs 
1. Sum of Squares 574.32 
2. Degree of Freedom 2 
3. Mean Square 287.16 
4. Model F Value 35.59 
5. P Value 0.0005 
6. R Square 0.9223 
Search for optimum formulation 
Based on acceptance criteria and desirability 
factor Design Expert (Version 8.0.6.1) suggested 
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two optimum formulations OF1, OF2 has been 
shown in Table 19. The value of desirability 
closest to 1 is considered most favourable. The 
value of desirabilities for two optimized 
formulations OF1 and OF2 were 1. Optimized 
batches were formulated with the suggested 
composition. The pre and post compression 
parameter shown in Table 20 of optimum 
formulations showed good flow properties and 
excellent compression characteristics. 
Table 19: Composition for Optimum batch 
OF1 and OF2. 
Sr. 
No. 
Ingredients OF1(mg) OF2 
(mg) 
1. Diclofenac 
Na 
100 100 
2. TSP 52.81 54.35 
3. MCC 82.25 79.83 
4. Lactose 107.94 108.82 
5. Talc 5 5 
6. Magnesium 
stearate 
2 2 
Table 20: Pre and post compression 
properties of optimized formulations (OF1, 
OF2). 
Sr. 
No. 
Parameter OFI OF2 
1. Bulk density 0. 531± 
0.019 
0.541± 
0.021 
2. Tapped 
density 
0.596 ± 
0.025 
0.601 ± 
0.027 
3. Angle of 
repose 
25.30 ± 
0.48 
22.35 ± 
0.59 
4. Carr’s index 10.09± 
0.203 
11.06 ± 
0.253 
5. Hardness 5.84 ± 
0.09 
5.74 ± 
0.084 
6. Friability 0.319± 
0.031 
0.367 ± 
0.046 
7. Weight 
variation 
348.5 ± 
0.85 
348.2 ± 
0.19 
8. Drug content 99.85 ± 
0.15 
99.25 ± 
0.11 
9. Thickness 
(mm) 
3.37 ± 
0.01 
3.19± 
0.08 
 
Table 21: Cumulative percent drug release 
for marketed and optimized batches. 
Sr. 
No. 
Cumulative Percent Drug Release 
 
 Time 
(h) 
Marketed Optimized 
Batch(OF1) 
Optimized 
Batch(OF2) 
1. 1 0.34±0.19 2.47±2.95 1.04±0.52 
2. 2 1.74±0.29 7.19±1.16 6.57±0.44 
3. 3 19.45±2.42 21.38±1.84 18.96±0.24 
4. 4 42.6±0.22 45.14±1.44 44.97±0.16 
5. 5 47.71±0.27 48.58±2.62 48.64±0.09 
6. 6 57.52±2.21 57.35±1.14 59.83±1.21 
7. 7 70.67±1.30 68.38±1.51 69.04±0.70 
8. 8 75.31±1.30 74.96±0.84 74.34±0.38 
9. 9 82.58±1.27 83.58±2.32 81.8±0.13 
10. 10 90.68±0.54 90.27±0.05 90.18±0.21 
Dissolution studies were carried out for 
optimized as well as marketed formulation. 
(Voveran – SR). The predicted values for these 
optimum formulations OF1 and OF2 at 10 hr 
were 91.001% and 90.16% respectively. In vitro 
dissolution study was carried out. The 
cumulative % drug release at 10 hr was found to 
be 90.27% and 90.18%. So it can be concluded 
that optimised batches obeys design expert 
characteristics. 
Dissolution study of marketed product 
Brand Name: Voveran-SR 
The dissolution study was carried out by USP II 
method. Following table illustrate the result. 
Table 22: Comparative study of in-vitro 
release of marketed tablet and selected batch. 
Sr.No. Time 
in Hrs 
Marketed 
Tablet 
% C.R. 
Selected  
Batch(OF1) 
% C.R. 
1. 1 0.34±0.19 2.47±2.95 
2. 2 1.74±0.29 7.19±1.16 
3. 3 19.45±2.42 21.38±1.84 
4. 4 42.6±0.22 45.14±1.44 
5. 5 47.71±0.27 48.58±2.62 
6. 6 57.52±2.21 57.35±1.14 
7. 7 70.67±1.30 68.38±1.51 
8. 8 75.31±1.30 74.96±0.84 
9. 9 82.58±1.27 83.58±2.32 
10. 10 90.68±0.54 90.27±0.05 
All values are expressed in mean ± SD, n=3 
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Comparison of in-vitro release between 
marketed formulation and optimized 
formulation 
 
Figure 11: Dissolution profile marketed and 
optimized formulation. 
Stability study 
The optimized batch OF1 was kept for 4 week 
stability study. The results of stability study 
have been shown in Table 23. The results of 
dissolution profile of optimized formulation for 
different days have been shown in Table 24. 
From the stability study and dissolution study 
data there is no significance change in 
characteristics of tablet formulation. So, it can 
be conclude that tablet passes the stability 
testing. 
Tableting properties as well as pre and post 
compression studies of granules were carried 
out. It was found that, angle of repose and 
Compressibility Index (Carr’s Index) of granules 
was found in the range of 25.98 ± 0.3 to 28.26 ± 
1.81 and 7.11 ± 2.99% to 12.66 ± 1.245% 
respectively. It indicates excellent to acceptable 
flowability of granules. The drug content of each 
formulation was found to be uniform in the 
range of from 98.00 ± 0.98% to 99.9 ± 0.65% 
which passes the pharmacopoeial limit. 
The in-vitro release study was carried out and 
revealed that cumulative % drug release in 
hydrophilic matrix tablet formulations were 
decreased with increase in concentration of 
polymer (TSP) This may be due to swollen 
polymer gel layer that was more thick as 
concentration of polymer increased, which was 
0
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Table 23: Stability study for final optimized batch OF1. 
Sr.No. Parameter 0 week 1 week 2 week 3 week 4 week 
1. Appearance Off White Off White Off White Off White Off White 
2. Thickness 3.00±0.01 3.36±0.05 3.52±0.06 3.43±0.09 3.12±0.14 
3. Hardness 5.84±0.09 5.75±0.05 5.64±0.06 5.20±0.09 5.89±0.05 
4. Drug Content 99.85±0.15 99.3±0.45 99.4±0.53 99.4±0.82 99.80±0.95 
Table 24: Dissolution study for optimized formulation. 
Sr. No. % Drug Release 
Time Initial 7 days 14 days 21 days 28 days 
1 1 2.47±2.95 2.30±1.59 1.95±0.85 2.93±0.89 2.50±0.95 
2 2 7.19±1.16 6.95±1.26 7.15±1.14 7.06±1.24 7.26±1.25 
3 3 21.38±1.84 20.85±1.54 21.23±1.53 20.85±1.42 20.42±1.34 
4 4 45.14±1.44 46.54±0.98 45..43±0.84 46.53±1.29 45.43±0.85 
5 5 48.58±2.62 49.24±0.65 47.46±1.23 48.46±0.68 47.96±1.47 
6 6 57.35±1.14 58.15±1.45 57.19±1.54 56.95±0.89 57.15±0.64 
7 7 68.38±1.51 67.24±0.58 66.95±0.85 68.65±0.75 68.25±0.65 
8 8 74.96±0.84 73.58±0.59 73.56±0.46 74.86±1.15 73.24±1.32 
9 9 83.58±2.32 84.46±1.28 82.16±0.94 83.42±1.34 82.34±0.83 
10 10 90.27±0.05 89.65±1.24 90.45±0.35 91.56±0.43 90.12±0.31 
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acting as barrier for release of drug . 
Thus as polymer concentration increased the 
drug release was retarded in the order as F9 > 
F6>F1 
The F1, F2, F3…F9 formulations could sustain 
the drug release up to 10 hours and more. 
At the primary stage the swelling of the tablet 
takes place due to the absorption of water in to 
the matrix tablet. In later stages, due to 
penetration of more fluid, the viscous gel layer 
of hydrophilic polymer expanded considerably 
and acted as effective barrier for drug diffusion. 
Formulation F1 to F9 could sustain the drug 
release up to 10 hour, But due to increasing 
concentration of the TSP in F7, F8, F9 
formulation cumulative release only up to 
78.24%, 76.47%and 73.12% respectively, 
Where as the F4, F5, F6 formulation sustain the 
drug release up to the 92.52%, 90.63% and 
87.57% respectively which is comparatively 
match with marketed preparation among all F1to 
F 9 preparations. 
Finally, the dissolution data for all trial 
formulations with different polymers was fitted 
into various kinetic models for depicting the 
mechanism of drug release of drug from the 
matrix tablets. 
All Formulations F1, F2…..F9 of Diclofenac 
sodium has shown Zero order as best fit model. 
The natural polymers can used to modify the 
release rate of Diclofenac Na from matrix 
tablets. The extension of release profile depends 
on type of polymer, its physicochemical and 
physicomechanical properties as well as its 
concentration in the formula. 
In swelling index study of the tablet as the 
polymer concentration increases, swelling index 
was found to increases. The swelling behavior 
indicated the rate at which this formulation 
absorbed water from dissolution media and 
swelled. It has been observed that the 
cumulative present drug release decreases with 
increasing concentration of the polymer. 
All Formulations were found to be stable at 
room temperature for a period of one month. 
There was no appreciable change in the physical 
properties, drug content and dissolution studies 
during the testing period. 
Conclusions    
Tamarind seed polysaccharide can be employed 
in dosage form to sustain the drug release. 
Tablet formulated with various concentrations of 
Tamarind seed polysaccharide (TSP) gives 
release up to 10 h and more. OF1 and OF2 both 
formulations give comparable release with 
marketed formulation. From the present work it 
can be conclude that, the objectives which were 
set at the beginning of the study got fulfilled.  
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